Search

Your search keyword '"Venturella, Roberta"' showing total 453 results
Start Over Author "Venturella, Roberta"
453 results on '"Venturella, Roberta"'

2. Prenatal identification of invasive placentation using ultrasound in women with placenta previa and prior cesarean delivery

Author

Califano, Gianluigi, Saccone, Gabriele, Maria Maruotti, Giuseppe, Bartolini, Giorgia, Quaresima, Paola, Morelli, Michele, Venturella, Roberta, Votino, Carmela, Morlando, Maddalena, Sarno, Laura, Miceli, Marta, Mazzulla, Rosanna, Collà Ruvolo, Claudia, Nazzaro, Giovanni, Locci, Mariavittoria, Guida, Maurizio, Berghella, Vincenzo, and Bifulco, Giuseppe

Published
2024
Full Text
View/download PDF

3. Oocyte competence is comparable between progestin primed ovarian stimulation with Norethisterone acetate (NETA-PPOS) and GnRH-antagonist protocols: A matched case-control study in PGT-A cycles

Author

Vaiarelli, Alberto, Cimadomo, Danilo, Ruffa, Alessandro, Rania, Erika, Pittana, Erika, Gallo, Cinzia, Fiorenza, Alessia, Alviggi, Erminia, Alfano, Simona, Carmelo, Ramona, Trabucco, Elisabetta, Alviggi, Carlo, Rosaria Campitiello, Maria, Rienzi, Laura, Maria Ubaldi, Filippo, and Venturella, Roberta

Published
2024
Full Text
View/download PDF

14. Oocyte competence is comparable between progestin primed ovarian stimulation with Norethisterone acetate (NETA-PPOS) and GnRH-antagonist protocols: A matched case-control study in PGT-A cycles

Author

Vaiarelli, Alberto, primary, Cimadomo, Danilo, additional, Ruffa, Alessandro, additional, Rania, Erika, additional, Pittana, Erika, additional, Gallo, Cinzia, additional, Fiorenza, Alessia, additional, Alviggi, Erminia, additional, Alfano, Simona, additional, Carmelo, Ramona, additional, Trabucco, Elisabetta, additional, Alviggi, Carlo, additional, Rosaria Campitiello, Maria, additional, Rienzi, Laura, additional, Maria Ubaldi, Filippo, additional, and Venturella, Roberta, additional

Published
2023
Full Text
View/download PDF

22. Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the LIBERTY long‐term extension study: A descriptive subgroup analysis in women with anemia at baseline.

Author

Venturella, Roberta, Lukes, Andrea S., Wu, Rui, McLean, Rachel, Rakov, Viatcheslav G., and Al‐Hendy, Ayman

Subjects
*UTERINE fibroids, *UTERINE hemorrhage, *MENORRHAGIA, *QUALITY of life, *ANEMIA, *FATIGUE (Physiology), *SUBGROUP analysis (Experimental design)
Abstract

Objective: To investigate the effects of 52 weeks of treatment with relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) on symptoms of uterine fibroids (UF) and quality of life (QoL) in women with heavy menstrual bleeding associated with UF and anemia (hemoglobin ≤10.5 g/dL) at baseline. Methods: This post hoc analysis included women from the LIBERTY long‐term extension study with anemia (hemoglobin concentration ≤10.5 g/dL) at pivotal study baseline and documented hemoglobin values at week 52 (anemia‐evaluable population). Treatment responders: women achieving a menstrual blood loss volume of <80 mL and a ≥50% reduction over the last 35 days of treatment. Anemia responders were women achieving a hemoglobin increase of >2 g/dL from baseline to week 52. Least squares (LS) mean changes from baseline in uterine fibroid symptom (UFS)‐QoL symptom severity, fatigue, and health‐related QoL total (HR‐QoL) and (sub)scale scores were calculated. Results: In total, 115 women were included in the anemia‐evaluable population. Of 39 anemia‐evaluable women who received continuous treatment with relugolix combination therapy for 52 weeks, 34 (87.2%) met treatment responder criteria and 23 (59.0%) were anemia responders. LS mean hemoglobin concentration increased by 29.4% at week 52. LS mean UFS‐QoL symptom severity and fatigue scores decreased by 38.5 and 31.9 points, respectively, and HR‐QoL total score increased by 41.6 points. Conclusion: In women with UF and a high disease burden due to anemia, relugolix combination therapy substantially improved hemoglobin levels, decreased distress due to symptoms, especially fatigue, over 52 weeks. Synopsis: Relugolix combination therapy improved hemoglobin, reduced fatigue and other symptoms, and improved quality of life in women with uterine fibroids and anemia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Лікування симптомів міоми матки з використанням комбінованої терапії релюголіксом.

Author

Al-Hendy, Ayman, Lukes, Andrea S., Poindexter III, Alfred N., Venturella, Roberta, Villarroel, Claudio, Critchley, Hilary O. D., Li, Yulan, McKain, Laura, Arjona Ferreira, Juan C., Langenberg, Andria G. M., Wagman, Rachel B., and Stewart, Elizabeth A.

Subjects
UTERINE tumors, STEROIDS, COMBINATION drug therapy, WOMEN, DRUG side effects, BLIND experiment, MENORRHAGIA, RANDOMIZED controlled trials, DESCRIPTIVE statistics, UTERINE fibroids, ESTRADIOL, GONADOTROPIN releasing hormone, DRUG efficacy, PAIN, DATA analysis software, CHEMICAL inhibitors
Abstract

Uterine fibroids are a common cause of heavy menstrual bleeding and pain. Treatment with the combination of relugolix (an oral gonadotropin-releasing hormonereceptor antagonist), estradiol, and norethindrone acetate, administered once daily, may have efficacy in women with uterine fibroids and heavy bleeding while avoiding hypoestrogenic effects. Methods. We conducted two replicate international, double-blind, 24-week, phase 3 trials involving women with fibroidassociated heavy menstrual bleeding. Participants were randomly assigned in a 1:1:1 ratio to receive once-daily placebo, relugolix combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate), or delayed relugolix combination therapy (40 mg of relugolix monotherapy, followed by relugolix combination therapy, each for 12 weeks). The primary efficacy end point in each trial was the percentage of participants with a response (volume of menstrual blood loss <80 ml and a ≥50% reduction in volume from baseline) in the relugolix combination therapy group, as compared with the placebo group. Key secondary end points were amenorrhea, volume of menstrual blood loss, distress from bleeding and pelvic discomfort, anemia, pain, fibroid volume, and uterine volume. Safety and bone mineral density were assessed. Result. A total of 388 women in trial L1 and 382 in trial L2 underwent randomization. A total of 73% of the participants in the relugolix combination therapy group in trial L1 and 71% of those in trial L2 had a response (primary end point), as compared with 19% and 15%, respectively, of those in the placebo groups (P<0.001 for both comparisons). Both relugolix combination therapy groups had significant improvements, as compared with the placebo groups, in six of seven key secondary end points, including measures of menstrual blood loss (including amenorrhea), pain, distress from bleeding and pelvic discomfort, anemia, and uterine volume, but not fibroid volume. The incidence of adverse events was similar with relugolix combination therapy and placebo. Bone mineral density was similar with relugolix combination therapy and placebo but decreased with relugolix monotherapy. Conclusions. Once-daily relugolix combination therapy resulted in a significant reduction in menstrual bleeding, as compared with placebo, and preserved bone mineral density in women with uterine fibroids. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. 'Better late than never but never late is better', especially in young women. A multicenter Italian study on diagnostic delay for symptomatic endometriosis

Author

Ida Pino, Gaia Maria Belloni, Valeria Barbera, Eugenio Solima, Davide Radice, Stefano Angioni, Saverio Arena, Valentino Bergamini, Massimo Candiani, Antonio Maiorana, Alberto Mattei, Ludovico Muzii, Luca Pagliardini, Maria Grazia Porpora, Valentino Remorgida, Renato Seracchioli, Paolo Vercellini, Fulvio Zullo, Errico Zupi, Michele Vignali, Busacca Mauro, D’Alterio Maurizio Nicola, Bonin Cecilia, Perandini Alessio, Viganò Paola, Bartiromo Ludovica, Ottolina Jessica, Schimberni Matteo, Incandela Domenico, Alio Walter, Perelli Federica, Piacenti Ilaria, Scaramuzzino Sara, Massarotti Claudia, Del Forno Simona, Berlanda Nicola, Somigliana Edgardo, Donati Agnese, Centini Gabriele, Lazzeri Lucia, La Banca Luca, Exacoustos Caterina, Sorrenti Giuseppe, and Venturella Roberta

Subjects
Reproductive Medicine, Endometriosis, adolescent endometriosis, chronic pelvic pain, diagnosis, diagnostic delay, Obstetrics and Gynecology, Pharmacology (medical)
Abstract

The aim of the study was to assess the length of diagnostic delay of symptomatic endometriosis in Italy and analyse the presence of correlations between the socio-demographic status of patients and the clinical characteristics/type of diagnosis. This multicenter cross-sectional questionnaire-based study was conducted in 10 tertiary Italian referral centres for diagnosis and treatment endometriosis. A total of 689 respondents with histologically proven endometriosis and onset of the disease with pain symptoms completed an on-line self-reported questionnaire written in their own language (World Endometriosis Research Foundation-Endometriosis Phenome and Biobanking Harmonisation Project-Endometriosis Patient Questionnaire–Minimum) evaluating endometriosis related symptoms, family history of endometriosis and chronic pelvic pain, demographic data, as well as medical, reproductive, and obstetric history. The mean diagnostic delay found was of 11.4 years. The mean time (14.8 years) from symptoms onset to diagnosis was significantly longer among patients aged 9–19 vs patients aged 20–30 (mean 6.9 years, p < 0.001) and patients aged 31–45 (mean 2.9, p < 0.001). No significant association were found between a delayed diagnosis and any of the clinically relevant factors such as the number or severity of the reported symptoms, familiarity, hormonal therapy intake or methodology of diagnosis. The mean diagnostic delay of endometriosis in Italy is about 11 years. The delay can be up to 4 years longer in patients with pain symptoms onset under 20 years. Educating clinicians and patients on pathologic nature of endometriosis related pelvic pain is advisable to reduce waiting time to diagnosis, especially for young women.

Published
2022

30. Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials.

Author

Venturella, Roberta, Rechberger, Tomasz, Zatik, János, Wagman, Rachel B., Zhu, Emily, Rakov, Viatcheslav G., and Petraglia, Felice

Subjects
*UTERINE fibroids, *MENORRHAGIA, *BONE density, *SUBGROUP analysis (Experimental design), *QUALITY of life, *PELVIC pain
Abstract

In the 24-week, phase 3 LIBERTY 1 (L1) and LIBERTY 2 (L2) trials, relugolix combination therapy (relugolix-CT (relugolix 40 mg, estradiol 1 mg, norethisterone acetate 0.5 mg)) reduced uterine fibroid (UF)-associated symptoms. This post hoc analysis assessed safety and efficacy of relugolix-CT in European women from L1/L2. Premenopausal women (aged 18–50 years) with UF-associated heavy menstrual bleeding (HMB) were randomized 1:1:1 in L1 (N = 388) and L2 (N = 382) to relugolix-CT or placebo for 24 weeks, or delayed relugolix-CT (relugolix 40 mg then relugolix-CT; 12 weeks each). Primary endpoint: proportion of responders (menstrual blood loss (MBL) <80 mL and reduction of ≥50% from baseline MBL volume) over the last 35 days of treatment. Secondary endpoints: MBL volume, amenorrhea, UF-associated pain, symptom severity, distress related to bleeding and pelvic discomfort, health-related quality of life (HRQoL). Safety endpoints included adverse event (AE) reporting and bone mineral density (BMD) assessment. In European women from L1/L2 (N = 124, 16%), a significantly greater proportion of treatment responders was observed with relugolix-CT vs. placebo (85.4% vs. 19.1%, respectively; nominal p <.0001). There were statistically significant improvements with relugolix-CT vs. placebo for several secondary endpoints: reduction in MBL volume, amenorrhea rate, proportion achieving mild-to-no pain, reduction in symptom severity and distress from bleeding and pelvic discomfort, and improvement in HRQoL. Incidence of AEs and percentage changes in BMD from baseline to week 24 were similar for relugolix-CT and placebo. In European women with UF and HMB, once-daily relugolix-CT vs. placebo improved UF-associated symptoms and preserved BMD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. A Plain Language Summary of the Safety of Relugolix Combination Therapy and Improvement in Symptoms in Women with Uterine Fibroids from the LIBERTY 1 and LIBERTY 2 Studies

Author

Al-Hendy, Ayman, primary, Lukes, Andrea S, additional, Poindexter, Alfred N, additional, Venturella, Roberta, additional, Villarroel, Claudio, additional, Critchley, Hilary OD, additional, Li, Yulan, additional, McKain, Laura, additional, Arjona Ferreira, Juan C, additional, Langenberg, Andria GM, additional, Wagman, Rachel B, additional, and Stewart, Elizabeth A, additional

Published
2023
Full Text
View/download PDF

35. Adenomyosis: What the Patient Needs

Author

Alabiso, Giulia, Alio, Luigi, Arena, Saverio, Barbasetti di Prun, Allegra, Bergamini, Valentino, Berlanda, Nicola, Busacca, Mauro, Candiani, Massimo, Centini, Gabriele, Di Cello, Annalisa, Exacoustos, Caterina, Fedele, Luigi, Fuggetta, Eliana, Gabbi, Laura, Geraci, Elisa, Imperiale, Ludovica, Lavarini, Elena, Incandela, Domenico, Lazzeri, Lucia, Luisi, Stefano, Maiorana, Antonio, Maneschi, Francesco, Mannini, Luca, Mattei, Alberto, Muzii, Ludovico, Pagliardini, Luca, Perandini, Alessio, Perelli, Federica, Pinzauti, Serena, Porpora, Maria Grazia, Remorgida, Valentino, Leone Roberti Maggiore, Umberto, Seracchioli, Renato, Solima, Eugenio, Somigliana, Edgardo, Tosti, Claudia, Venturella, Roberta, Vercellini, Paolo, Viganò, Paola, Vignali, Michele, Zannoni, Letizia, Zullo, Fulvio, and Zupi, Errico

Published
2016
Full Text
View/download PDF

40. Maternal and perinatal complications according to maternal age: A systematic review and meta-analysis

Author

Saccone, Gabriele, Gragnano, Elisabetta, Ilardi, Bernadette, Marrone, Vincenzo, Strina, Ida, Venturella, Roberta, Berghella, Vincenzo, Zullo, Fulvio, Saccone, Gabriele, Gragnano, Elisabetta, Ilardi, Bernadette, Marrone, Vincenzo, Strina, Ida, Venturella, Roberta, Berghella, Vincenzo, and Zullo, Fulvio

Subjects
Adult, Perinatal Death, Infant, Newborn, Pregnancy Outcome, Obstetrics and Gynecology, General Medicine, Middle Aged, Stillbirth, Pregnancy, Humans, Premature Birth, Female, Maternal Age, Retrospective Studies
Abstract

To evaluate the risk levels for maternal and perinatal complications at40,45 and50 years old compared with younger controls.Electronic databases were searched from their inception until March 2021. We included studies reporting pregnancy outcome in pregnant women aged 40, 45, and 50 years or older compared with controls at the time of delivery. Case reports and case series were excluded. The primary outcome was the incidence of stillbirth. Meta-analysis was performed using the random effects model of DerSimonian and Laird, to produce summary treatment effects in terms of relative risk (RR) with 95% confidence interval (CI). Heterogeneity was measured using ITwenty-seven studies, including 31 090 631 women, were included in the meta-analysis. The overall quality of the included studies was moderate to high. Most of the included studies were retrospective cohort studies (21/27), four were population-based studies, and two were cross-sectional studies. Women aged ≥40 years had significantly higher risk of stillbirth (RR 2.16, 95% CI 1.86-2.51), perinatal mortality, intrauterine growth restriction, neonatal death, admission to neonatal intensive care unit, pre-eclampsia, preterm delivery, cesarean delivery, and maternal mortality compared with women younger than 40 years old (RR 3.18, 95% CI 1.68-5.98). The increased risks for maternal mortality were 42.76 and 11.60 for women older than 50 years and for those older than 45 years, respectively, whereas those for stillbirth were 3.72 and 2.32. The risk of stillbirth and cesarean delivery was significantly higher in women45 years compared with those aged 40-45 years, and in those aged50 years compared with those aged 45-50 years. The risk of maternal mortality was significantly higher in women aged50 years compared with those aged 40-45 (RR 60.40, 95% CI 13.28-274.74).The risk of stillbirth, cesarean delivery, and maternal mortality increases with advancing maternal age. The risk ratios for maternal mortality were 3.18, 11.60, and 42.76 in women older than 40, older than 45, and older than 50 years, respectively. These data should be used when women with advanced maternal age are counseled regarding their risk in pregnancy.The review was registered with the PROSPERO International Prospective Register of Systematic Reviews (registration No.: CRD42020208788).

Published
2021

49. Successful Vaginal Delivery after Induction of Labour in a Patient Treated for Non-Hodgkin’s Lymphoma of the Cervix: A Case Report and Literature Review

Author

Quaresima, Paola, Saccone, Gabriele, Zuccalà, Valeria, Guarascio, Giuseppe, Leo, Livio, Amendola, Giuseppina, Zullo, Fulvio, Morelli, Michele, and Venturella, Roberta

Subjects
Article Subject, immune system diseases, hemic and lymphatic diseases
Abstract

Objective. Primary non-Hodgkin’s lymphomas of the cervix are rare; they represent about 1% of all cases. There are no available guidelines regarding the safest mode of delivery after treatment and resolution of a cervical lymphoma. Case Report. We report the first case of a successful vaginal delivery after induction of labour in a woman recovered from a primary large B-cell lymphoma of the cervix and a literature review. Conclusion. In carefully selected patients with fully treated non-Hodgkin’s lymphoma of the cervix with no residual disease, induction of labour via prostaglandins pessary may be a safe option if indicated.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results